In the absence of estrogen, RAR-fusion oncoproteins endow ECoM-G cells with RA sensitivity
| Cells . | Treatment . | Immature cells (%) . | Mature granulocytes (%) . |
|---|---|---|---|
| ECoM-G parental (+ E2) | None | 100 | 0 |
| 4 d 10 μM atRA | 100 | 0 | |
| PML/RAR (− E2) | None | 86 | 14 |
| 4 d 10 μM atRA | 1 | 99 | |
| PLZF/RAR (− E2) | None | 95 | 5 |
| 4 d 10 μM atRA | 12 | 88 |
| Cells . | Treatment . | Immature cells (%) . | Mature granulocytes (%) . |
|---|---|---|---|
| ECoM-G parental (+ E2) | None | 100 | 0 |
| 4 d 10 μM atRA | 100 | 0 | |
| PML/RAR (− E2) | None | 86 | 14 |
| 4 d 10 μM atRA | 1 | 99 | |
| PLZF/RAR (− E2) | None | 95 | 5 |
| 4 d 10 μM atRA | 12 | 88 |
As shown in Figure 7, ECoM-G cells blocked in differentiation by PML/RARα or PLZF/RARα, but not parental cells, demonstrate RA-induced morphologic differentiation. This table summarizes the results from at least 200 Wright-Giemsa–stained cells untreated or treated 4 days with 10 μM atRA.